Influenza immune globulin - Emergent BioSolutions

Drug Profile

Influenza immune globulin - Emergent BioSolutions

Alternative Names: Anti-influenza immune globulin intravenous (Human); FLU IGIV; Intravenous hyperimmune immunoglobulin; NP 025

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emergent BioSolutions
  • Developer National Institute of Allergy and Infectious Diseases; University of Minnesota
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza A virus infections; Influenza B virus infections

Most Recent Events

  • 17 Nov 2017 Emergent Biosciences initiates enrolment in a phase II trial for Influenza-A virus infection (IV) (NCT03315104)
  • 30 Oct 2017 Emergent Biosciences plans a phase II trial for Influenza-A virus infection (IV) in November 2017 (NCT03315104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top